Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

PharmaCyte Biotech Inc

PMCB ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.33

▼ -2.45%

Market Cap $3.59M · Vol 1.34K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.59M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

22.54

Momentum

Beta

0.76

vs Market

52W High

$1.51

77.83% below

52W Low

$0.33

0.24% above

Volume

1.34K

Avg 8.59K

P/B

0.23

Price-to-book

ROE

N/A

Return on equity

Free Float

94.26%

Public shares

Shariah Compliance8 STANDARDS

✗ PharmaCyte Biotech Inc (PMCB) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PMCB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.56%

-20.29%

-43.27%

-55.96%

YTD

-53.77%

-65.92%

-83.35%

-88.13%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-19,424,650.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-38.12% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.23
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	10.74M

Technical Indicators

50-Day SMA	$0.43
200-Day SMA	$0.65
RSI (14)	22.54
Beta	0.76
52-Week High	$1.51
52-Week Low	$0.33

Volume Today	1.34K
Avg Daily Volume (30D)	8.59K
Relative Volume	0.16x
Volatility (10D)	28.03
Volatility (30D)	59.98
Free Float	94.26%

Analyst Consensus

N/A

Current Price $0.33

Mean Target N/A

52W Low$0.33 52W High$1.51

Current

Target

$0.33 $1.51

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S69496

ISINUS71715X2036

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.69% ARGX.BR argenx SE +1.76% ARGX argenx SE +1.05% GMAB.CO Genmab A/S +29.06% GMAB Genmab A/S +28.25%

Company Profile

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.